title: Depression of factor XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy.
abstract: Twenty patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator (rt-PA) had endogenous factor XII-dependent fibrinolytic activity levels measured throughout the hospital period and those levels were prospectively correlated with the incidence of recurrent myocardial infarction until 8 weeks after hospital discharge. Within the follow-up period, recurrent myocardial infarction was observed in 8 patients, whereas the remaining 12 patients showed no clinical evidence of recurrence. The patients in the reinfarction group were characterized by a more pronounced depletion of and sustained lower levels of factor XII-dependent fibrinolytic activity than were the patients with no reinfarction (p less than 0.05). The decrease in fibrinolytic activity during rt-PA therapy was significantly associated with a depletion of functional alpha 2-antiplasmin, the primary plasmin inhibitor. These results indicate that, paradoxically, coronary thrombolysis with rt-PA involves depletion of endogenous factor XII-dependent fibrinolytic activity levels, which constitutes a risk for early myocardial reinfarction.
authors.affiliation: Department of Clinical Chemistry, Ribe County Hospital, Esbjerg, Denmark.
authors.forename: S
authors.initials: S
authors.lastname: Munkvad
authors.forename: J
authors.initials: J
authors.lastname: Jespersen
authors.forename: J
authors.initials: J
authors.lastname: Gram
authors.forename: C
authors.initials: C
authors.lastname: Kluft
mesh_terms: D000368:Aged; D005174:Factor XII / Q000032:analysis*; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D000979:alpha-2-Antiplasmin / Q000032:analysis
chemical_list: D011994:Recombinant Proteins; D000979:alpha-2-Antiplasmin; D005174:Factor XII; D010959:Tissue Plasminogen Activator